Cargando…

Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease

Huntington's disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have developed HTT gene-silencing approaches based on ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miniarikova, Jana, Zanella, Ilaria, Huseinovic, Angelina, van der Zon, Tom, Hanemaaijer, Evelyn, Martier, Raygene, Koornneef, Annemart, Southwell, Amber L, Hayden, Michael R, van Deventer, Sander J, Petry, Harald, Konstantinova, Pavlina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014463/ https://www.ncbi.nlm.nih.gov/pubmed/27003755 http://dx.doi.org/10.1038/mtna.2016.7

Ejemplares similares

Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients
por: Martier, Raygene, et al.
Publicado: (2019)

In-Depth Characterization of a Mifepristone-Regulated Expression System for AAV5-Mediated Gene Therapy in the Liver
por: Liefhebber, Jolanda M., et al.
Publicado: (2019)

Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100
por: Maczuga, Piotr, et al.
Publicado: (2012)

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease
por: Miniarikova, J, et al.
Publicado: (2017)

AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes
por: Keskin, Sonay, et al.
Publicado: (2019)

Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy
por: Martier, Raygene, et al.
Publicado: (2019)

Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock
por: Martier, Raygene, et al.
Publicado: (2020)

In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs
por: Borel, Florie, et al.
Publicado: (2011)

AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models
por: Spronck, Elisabeth A., et al.
Publicado: (2019)

Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease
por: Caron, Nicholas S, et al.
Publicado: (2020)

Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy
por: Maczuga, Piotr, et al.
Publicado: (2013)

AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model
por: Evers, Melvin M., et al.
Publicado: (2018)

Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression
por: Southwell, Amber L., et al.
Publicado: (2015)

Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver
por: Maczuga, P, et al.
Publicado: (2014)

Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease
por: Ehrnhoefer, Dagmar E., et al.
Publicado: (2018)

Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease
por: Martier, Raygene, et al.
Publicado: (2019)

Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology
por: Spronck, Elisabeth A., et al.
Publicado: (2021)

Emerging Therapies for Huntington’s Disease – Focus on N-Terminal Huntingtin and Huntingtin Exon 1
por: van der Bent, M Leontien, et al.
Publicado: (2022)

Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
por: Skotte, Niels H., et al.
Publicado: (2014)

Making (anti-) sense out of huntingtin levels in Huntington disease
por: Evers, Melvin M, et al.
Publicado: (2015)

Huntingtin Aggregates in the Olfactory Bulb in Huntington’s Disease
por: Highet, Blake, et al.
Publicado: (2020)

Biological Aging and the Cellular Pathogenesis of Huntington’s Disease
por: Machiela, Emily, et al.
Publicado: (2020)

Phosphorylation of huntingtin at residue T3 is decreased in Huntington’s disease and modulates mutant huntingtin protein conformation
por: Cariulo, Cristina, et al.
Publicado: (2017)

Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin
por: Tan, Z, et al.
Publicado: (2015)

Secreted therapeutics: monitoring durability of microRNA-based gene therapies in the central nervous system
por: Sogorb-Gonzalez, Marina, et al.
Publicado: (2021)

Salivary levels of total huntingtin are elevated in Huntington’s disease patients
por: Corey-Bloom, Jody, et al.
Publicado: (2018)

Recent Trends in Detection of Huntingtin and Preclinical Models of Huntington's Disease
por: Mantha, Neelima, et al.
Publicado: (2014)

Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
por: Rook, Morgan E., et al.
Publicado: (2022)

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
por: Van Raamsdonk, Jeremy M, et al.
Publicado: (2006)

Huntington’s Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy
por: Sari, Youssef
Publicado: (2011)

Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington’s Disease
por: Osmand, Alexander P., et al.
Publicado: (2016)

A Fresh Look at Huntingtin mRNA Processing in Huntington’s Disease
por: Romo, Lindsay, et al.
Publicado: (2018)

Rac1 Activity Is Modulated by Huntingtin and Dysregulated in Models of Huntington’s Disease
por: Tousley, Adelaide, et al.
Publicado: (2019)

Polyglutamine expansion affects huntingtin conformation in multiple Huntington’s disease models
por: Daldin, Manuel, et al.
Publicado: (2017)

Huntington’s Disease Protein Huntingtin Associates with its own mRNA
por: Culver, Brady P., et al.
Publicado: (2016)

Analysis of mutant and total huntingtin expression in Huntington’s disease murine models
por: Fodale, Valentina, et al.
Publicado: (2020)

Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease
por: Miguez, Andrés, et al.
Publicado: (2023)

Salivary Huntingtin protein is uniquely associated with clinical features of Huntington’s disease
por: Parkin, Georgia M., et al.
Publicado: (2023)

Striatal Synaptic Dysfunction and Hippocampal Plasticity Deficits in the Hu97/18 Mouse Model of Huntington Disease
por: Kolodziejczyk, Karolina, et al.
Publicado: (2014)

A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease
por: Martin, D. D. O., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b94rp5l8v1elldtgl380j2u1l5